Metronomic oral vinorelbine in patients with advanced non-small cell lung cancer progressing after nivolumab immunotherapy: a retrospective analysis

Vittorio Gebbia, Maria Rosaria Valerio, Gianfranco Mancuso, Nicolò Borsellino, Vittorio Gebbia, Giuseppe Banna, Giuseppina Savio, Hector Soto Parra, Giusi Blanco, Marco Maria Aiello, Dario Piazza, Hector Soto Parra, Mario Lo Mauro, Marco Maria Aiello, Giusi Blanco, Paolo Vigneri, Livio Blasi, Francesco Verderame, Dario Giuffrida, Maria Rosaria ValerioGianfranco Mancuso, Mario Lo Mauro

Risultato della ricerca: Articlepeer review


The availability of immune checkpoint inhibitors has deeply changed the therapeutic scenario of patients with advanced non-small cell lung cancer (NSCLC). Up until now, chemotherapy still represents the first-line treatment for patients with advanced NSCLC not harbouring genetic mutations or lacking high expression of programmed death ligand even if the addition of immunotherapy to first-line chemotherapy has recently been shown to improve clinical outcome. We carried out a multi-institutional retrospective analysis on third-line chemotherapy with metronomic oral vinorelbine (VNR) in a series of patients with metastatic NSCLC pre-treated with first-line chemotherapy and second-line immunotherapy.
Lingua originaleEnglish
pagine (da-a)1113-1120
Numero di pagine8
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cita questo